Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Primary Biliary Cholangitis Therapeutics Market

Primary Biliary Cholangitis Therapeutics Market Share

Report ID: GMI10014
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Primary Biliary Cholangitis Therapeutics Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies that manufacture advanced primary biliary cholangitis therapeutics products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for primary biliary cholangitis therapeutics.

Primary Biliary Cholangitis Therapeutics Market Companies

Prominent players operating in the market are as mentioned below:

Abbott Laboratories
Arlak Biotech Pvt. Ltd
Cadila Pharmaceuticals
Drag Pharma
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Ipsen
Leeford Healthcare Limited
Lupin
Sun Pharmaceuticals Ltd.
Viatris, Inc. (Mylan N.V.)
Vivaldis

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Global primary biliary cholangitis (PBC) therapeutics industry was valued at USD 677.2 million in 2023 and is anticipated to register 7.1% CAGR between 2024 and 2032 due to the rising prevalence of primary biliary cholangitis and increasing advancements in diagnostic technologies.

The human segment in the primary biliary cholangitis (PBC) therapeutics market held 88.2% revenue share in 2023 led by the rising prevalence of primary biliary cholangitis in women and well-developed healthcare infrastructure for effective treatment delivery.

North America primary biliary cholangitis (PBC) therapeutics market held 45.2% revenue share in 2023 due to the high prevalence of PBC and rigorous regulatory standards set by the U.S. Food and Drug Administration (FDA) ensure the safety, efficacy, and quality.

Abbott Laboratories, Arlak Biotech Pvt. Ltd, Cadila Pharmaceuticals, Drag Pharma, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Ipsen, Leeford Healthcare Limited, Lupin, Sun Pharmaceuticals Ltd., Viatris, Inc. (Mylan N.V.), and Vivaldis.